The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.
 
Hans-Georg Wirsching
Consulting or Advisory Role - Roche Pharma AG
Research Funding - Roche Pharma AG (Inst)
 
Ghazaleh Tabatabai
Honoraria - Bristol-Myers Squibb
Speakers' Bureau - Medac
Travel, Accommodations, Expenses - Medac
 
Ulrich Roelcke
No Relationships to Disclose
 
Andreas Felix Hottinger
No Relationships to Disclose
 
Andrea Schmid
No Relationships to Disclose
 
Ludwig Plasswilm
No Relationships to Disclose
 
Katrin Lisa Conen
Consulting or Advisory Role - MSD; Roche Pharma AG
 
Thomas Hundsberger
Consulting or Advisory Role - Roche Pharma AG
 
Francesca Caparrotti
No Relationships to Disclose
 
Roger Von Moos
Honoraria - Roche
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bayer; Merck Serono
 
Christian Alexander Riklin
No Relationships to Disclose
 
Luca Remonda
No Relationships to Disclose
 
Patrick Roth
Consulting or Advisory Role - Bristol-Myers Squibb; Molecular Partners; MSD; Novartis; Roche Pharma AG
Research Funding - MSD
 
Leonhard Held
No Relationships to Disclose
 
Elisabeth Jane Rushing
No Relationships to Disclose
 
Adrian Ochsenbein
No Relationships to Disclose
 
Michael Weller
Honoraria - ImmunoCellular Therapeutics; Lilly; Merck Serono; MSD; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celldex; Lilly; Magforce; Merck Serono; Pfizer; Roche; Teva
Research Funding - Acceleron Pharma (Inst); Actelion (Inst); Bayer (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); OGD2 Pharma (Inst); Piqur (Inst); Roche (Inst)